Global Blood Therapeutics, Inc. short interest in 2022
In 2022, Global Blood Therapeutics, Inc.'s disclosed short interest ran from 14.86% of shares outstanding on 14 Jan 2022 to 10.05% on 30 Sep 2022, a change of -4.81 percentage points. The year's high was 18.02% on 13 May 2022 and its low 8.60% on 15 Aug 2022, averaging 14.71% across 18 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.52 days on 31 Mar 2022. Full history: Global Blood Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022
2022 in figures
- Start of year
- 14.86% (14 Jan 2022)
- End of year
- 10.05% (30 Sep 2022)
- Change
- -4.81 pp
- High
- 18.02% (13 May 2022)
- Low
- 8.60% (15 Aug 2022)
- Average
- 14.71%
- Highest days to cover
- 12.52 (31 Mar 2022)
- SEC filings marked
- 5
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 14.86% | 8.08 | |
| 31 Jan 2022 | 15.25% | 5.81 | |
| 15 Feb 2022 | 16.01% | 9.91 | |
| 28 Feb 2022 | 17.52% | 8.46 | 10-K filed, results (8-K) |
| 15 Mar 2022 | 16.85% | 10.68 | |
| 31 Mar 2022 | 16.85% | 12.52 | |
| 14 Apr 2022 | 16.23% | 10.72 | |
| 29 Apr 2022 | 16.94% | 12.21 | |
| 13 May 2022 | 18.02% | 5.48 | 10-Q filed, results (8-K) |
| 31 May 2022 | 16.62% | 9.08 | |
| 15 Jun 2022 | 16.36% | 6.67 | |
| 30 Jun 2022 | 15.13% | 4.22 | |
| 15 Jul 2022 | 14.18% | 8.65 | |
| 29 Jul 2022 | 14.39% | 9.56 | |
| 15 Aug 2022 | 8.60% | 1.00 | 10-Q filed |
| 31 Aug 2022 | 10.22% | 1.96 | |
| 15 Sep 2022 | 10.79% | 2.31 | |
| 30 Sep 2022 | 10.05% | 2.69 |
See also: Global Blood Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.